Page 38 - Eua News Today : Breaking News, Live Updates & Top Stories | Vimarsana

"washington post." you say, number one, shots for younger kids. this could be sooner rather than later, which, of course, is good news. in learning this, do you think changes could come? could this official request for an eua, could that change the time line at all? >> i really hope not because the fda has already said that they're approached authorization for the vaccines for 5 to 11-year-olds with urgency. this is the reason why they already set an advisory committee meeting for october 26th, pending pfizer submitting their application on time. submitting it now, today, gives the fda enough ...

New this morning, astrazeneca is asking the fda for emergency use authorization for its antibody therapy meant to prevent symptomatic covid-19. this as johnson & johnson seeking eua for a booster dose of its one shot vaccine. >> joining us now to talk through this, dr. carlos del rio, executive associate dean of emory university school of medicine at grady health system. always good to see you. let's start with this j&j request for an eua for a booster shot to its one dose vaccine. there has been a lot of talk about what about the j&j folks? do you see any reason that it would not be granted, ...

In conversation with Dr Sabyasachi Chatterjee, president of the All India People's Science Network.

Very exciting. that's a different committee that meets. that's not the vaccine committee, and obviously a very important story, a very busy month of october, and i think americans can be happy and welcome the news that fda is on it, and all of these interventions may be poised to benefit us. but we doen't want to pre-judge the data. safety comes first. safety and efficacy are the two tasks we take first. >> of course there are steps between the submission of the data for pfizer for children under 12 for vaccines, and getting that eua. but i wonder when you look at the polling of parents who sa...

Patients. they'll request emergency use authorization from the fda as soon as possible. earlier this evening, i spoke with dr. jonathan reiner, a cnn medical analyst. >> unlike monoclonal antibodies which are always effective, this drug is orally available, so we'll be able to prescribe this to folks. they'll take a five-day course and hopefully be able to stay homes not come in for an intravenous infusion and keep folks out of the hospital. it's really very promising news. merck has promised the united states 1.7 million courses of this drug. they'll produce about 10 million courses over the ...